Full Cohort,N = 2255 | <100% Baseline Coverage Subset, N = 725 | Recent ART Initiators Subset, N = 416 | |
---|---|---|---|
Covariate | Adjusted Odds Ratio (95% CI); P-value | ||
Age (per year) | 1.03 (1.01–1.04); P < 0.001 | 1.02 (1.01–1.03); P = 0.001 | 1.03 (1.01–1.06); P = 0.016 |
Female gender | 1.55 (1.26–1.90); P < 0.001 | 1.32 (1.03–1.68); P = 0.027 | 0.92 (0.54–1.56); P = 0.751 |
Prior ART duration (per 30 days) | – | – | – |
Prescription length (per 30 days) | 1.28 (1.27–1.29); P < 0.001 | 1.17 (1.16–1.19); P < 0.001 | 1.31 (1.28–1.34); P < 0.001 |
First line regimen | 2.70 (2.33–3.12); P <0.001 | 4.30 (3.62–5.11); P < 0.001 | 5.52 (3.92–7.77); P < 0.001 |
Fixed dose combination | 2.71 (2.62–2.81); P < 0.001 | 3.51 (3.33–3.70); P < 0.001 | 2.88 (2.67–3.10); P < 0.001 |
During-program period | 0.61 (0.56–0.66); P < 0.001 | 1.56 (1.42–1.71); P < 0.001 | 0.53 (0.45–0.63); P < 0.001 |
Pre-program period coverage (by Group): | |||
Exposed vs. Unexposed | 1.05 (0.79–1.39); P = 0.732 | 1.00 (0.72–1.39); P = 0.992 | 2.53 (1.11–5.77); P = 0.028 |
Unknown vs. Unexposed | 1.60 (1.02–2.51); P = 0.040 | 1.48 (0.85–2.57); P = 0.166 | 3.07 (1.01–9.35); P = 0.049 |
Program Effect (= During-program period coverage, by Group, adjusting for the variables above): | |||
Exposed vs. Unexposed | 1.23 (1.13–1.34); P < 0.001 | 1.29 (1.17–1.43); P < 0.001 | 1.17 (0.97–1.42); P = 0.101 |
Unknown vs. Unexposed | 0.47 (0.41–0.54); P < 0.001 | 0.67 (0.57–0.80); P < 0.001 | 0.33 (0.24–0.45); P < 0.001 |